Assay News and Research

RSS

Scientists discover serum biochemical signature that predicts Alzheimer's

Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer's disease months or even years before the first symptoms of the disease occur. The goal of the new collaboration between VTT and GE Healthcare is to validate this biomarker in a large patient cohort as well as to discover novel biomarker candidates.

27 Jun 2012

Seahorse Bioscience launches XF Palmitate-BSA FAO Reagent for FAO assays

Seahorse Bioscience, the world leader in manufacturing instrumentation and assay kits for measuring cellular metabolism, has announced the launch of its newest product, the XF Palmitate-BSA FAO Reagent, eliminating the need for radioactivity in fatty acid oxidation (FAO) assays.

27 Jun 2012

HemoGenix receives first Master File Number from FDA CBER for HALO-96 PQR

HemoGenix announced today that FDA CBER has given HemoGenix its first Master File Number for an in vitro blood stem cell potency, quality and release assay (HALO-96 PQR) for cellular therapy products used for stem cell transplantation purposes. HALO-96 PQR is the first commercially available stem cell potency assay for cellular therapy products.

27 Jun 2012

MRI scans determine whether chemotherapy is working long before tumors shrink

Studies on some 55 U.S. men and women with potentially deadly liver or pancreatic cancers show that specialized MRI scans can tell within a month whether highly toxic chemotherapy is working and killing tumor cells long before tumors actually shrink – or fail to shrink.

26 Jun 2012

Report on the global market for breast cancer diagnostics and drug technologies

Breast Cancer Diagnostic and Drug market are recovering after significant slowdown during the global recession. Having accurate market data and analysis will be essential to companies seeking to compete on the global stage as the market reemerges into success.

26 Jun 2012

Scientists identify novel animal reservoir for tick-borne diseases

A team of scientists at Washington University in St. Louis has been keeping a wary eye on emerging tick-borne diseases in Missouri for the past dozen years, and they have just nailed down another part of the story.

23 Jun 2012

Indica Labs' image analysis algorithm portfolio integrated into Leica Microsystems' digital pathology solution

Leica Microsystems, world-leading provider of Total Digital Pathology solutions, and Indica Labs, developing excellence in image analysis for Digital Pathology, today announce the integration of Indica Labs' advanced image analysis algorithm portfolio into Leica Microsystems digital pathology solution.

22 Jun 2012

FDA approves CDC DENV-1-4 Real Time RT PCR Assay to treat dengue

The Centers for Disease Control and Prevention has developed a new diagnostic test to detect the presence of dengue virus in people with symptoms of dengue fever or dengue hemorrhagic fever. The test, called the CDC DENV-1-4 Real Time RT PCR Assay, has been authorized by the Food and Drug Administration for use in the United States and can be performed using equipment and supplies many public health laboratories already use to diagnose influenza.

21 Jun 2012

AOAC certifies InstantLabs Salmonella Species Food Safety Kit

InstantLabs Medical Diagnostics Corporation, developer of the portable Hunter Accelerated Real-Time PCR system, today announced that its Salmonella Species Food Safety Kit has been certified as AOAC Performance-Tested (AOAC PTM Cert. No. 031202) by the AOAC Research Institute (AOAC-RI) across four key food matrices.

19 Jun 2012

T2Endotoxin assay extends reach of T2MR detection

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of data on endotoxin detection at the American Society for Microbiology General Meeting, June 16-19, 2012, in San Francisco, CA.

18 Jun 2012

NextGen commercializes new assay for identification of biomarkers in brain disorders

NextGen Group Plc, the AIM listed company developing its own diagnostics product pipeline and providing diagnostic biomarker development services, announces the commercialisation of a new assay for the identification of diagnostic biomarkers in brain disorders in animal models.

15 Jun 2012

Enzo Biochem third quarter total revenue increases 4% to $26 million

Enzo Biochem, Inc. today reported results for the fiscal third quarter ended April 30, 2012.

12 Jun 2012

New liquid stable homocysteine kit from Randox

The new liquid stable homocysteine kit from Randox provides a convenient and accurate method for the determination of homocysteine in human serum and plasma. Homocysteine is a potential indicator of a number of disease markers and should therefore be an integral part of a laboratory’s testing menu.

From Randox Laboratories Ltd. 11 Jun 2012

Biomedical engineers develop SMART detector for flu diagnosis

In April 2009, the world took notice as reports surfaced of a virus in Mexico that had mutated from pigs and was being passed from human to human. The H1N1 "swine flu," as the virus was named, circulated worldwide, killing more than 18,000 people, according to the World Health Organization. The Centers for Disease Control and Prevention in the United States said it was the first global pandemic in more than four decades.

11 Jun 2012

Strand, Trovagene enter MOU to license and validate HPV assay technology

Trovagene, Inc., a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation.

8 Jun 2012

Roche files TnT-hs assay 510(k) submission with FDA for use on laboratory analyzers

Roche announced today that it has filed a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a fully automated TnT-hs assay for use on Roche's full portfolio of laboratory analyzers.

From Roche Sequencing and Life Science 8 Jun 2012

bioTheranostics’ CancerTYPE ID molecular test improves overall survival for patients with CUP

bioTheranostics, developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced study results showing that tumor profiling with its CancerTYPE ID molecular test helped guide site-specific chemotherapy and improve overall survival for patients with carcinoma of unknown primary site.

6 Jun 2012

Novel assay accurately detects trisomy 21 or 18 from maternal blood samples

Current screening strategies for Down syndrome, caused by fetal trisomy 21 (T21), and Edwards syndrome, caused by fetal trisomy 18 (T18), have false positive rates of 2 to 3%, and false negative rates of 5% or higher. Positive screening results must be confirmed by amniocentesis or chorionic villus sampling, which carry a fetal loss rate of approximately 1 in 300 procedures. Now an international, multicenter cohort study finds that a genetic test to screen for trisomy 21 or 18 from a maternal blood sample is almost 100% accurate.

6 Jun 2012

HDL to offer testing services based on Critical Diagnostics' Presage ST2 Assay

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases and Health Diagnostic Laboratory, Inc. (HDL, Inc.), announced today an agreement under which HDL, Inc. will soon offer ST2 testing services based on Critical Diagnostics' Presage ST2 Assay.

5 Jun 2012